An AI-driven solution designed for dense breast mammography. Pioneering in CEM, it aids radiologists in detecting breast anomalies with heightened accuracy while reducing unwarranted biopsies.
Denise, the flagship solution by MICA AI Medical, is an avant-garde AI algorithm aptly named “Dense Breast Innovative System.” With 40% of women possessing dense breasts, traditional mammography often falls short in diagnostic accuracy. Denise, designed as a decision-support aid for radiologists, fills this diagnostic void. Notably developed and rigorously validated at the esteemed SHEBA Hospital, Denise elevates mammography accuracy by a staggering 24% while curbing unnecessary biopsies by 40%. Celebrated as the first AI solution for CEM (mammography tailored for dense breast tissue), Denise has already garnered approval from the Israeli Ministry of Health and awaits endorsement by the US FDA. It stands not merely as an algorithm but as a harbinger of hope and enhanced medical accuracy for countless women globally.
Concentrates on the breast, specifically designed for dense breast tissue, using mammography as the imaging modality.
Intended to be utilized for routine mammography screenings, particularly for women identified with dense breast tissue, ensuring that this significant population receives the most accurate diagnosis possible.
Dense breast tissue detection and characterization, complete with CEM to aid in a more precise mammography diagnosis.
Approved by the Israeli Ministry of Health. Submitted and awaiting approval from the US FDA (Class 2 – 510k) – spotlighted as the first-ever AI for CEM.
MICA AI Medical, poised at the forefront of breast cancer diagnostics, embodies a vision to reduce the global burden of breast cancer by one-third. Rooted in its mission to furnish radiologists with advanced AI technology, MICA endeavors to make mammogram reading both efficient and precise, a response to the escalating complexity of mammograms. The company's solemn promise is manifold – from offering unique solutions for dense breast tissue to saving lives. Their team, an amalgamation of experts from diverse fields, reflects their commitment to excellence, all converging under the leadership of CEO & Co-founder, Lior Wayn. Drawing inspiration from the United Nations Sustainable Development Goals, MICA is not just a business but a beacon of sustainability and betterment in healthcare.
by ClariPi Inc.
The ClariSIGMAM is an innovative breast cancer prediction marker. It is a breast
by Koios
Koios DS™ Breast is revolutionizing breast cancer diagnostics with AI-powered
Let’s collaborate to harness the transformative power of these advanced technologies, propelling your medical practice to unprecedented levels of diagnostic accuracy, efficiency, and patient care.
Redeem your demo!
